{"DataElement":{"publicId":"5731480","version":"1","preferredName":"Molecular Analysis Laboratory Procedure EBNA-2 PCR Finding Text","preferredDefinition":"Text that describes the result for Epstein-Barr Nuclear Antigen 2 (EBNA-2) found through molecular analysis using PCR.","longName":"EBNA2_PCR_FND_TXT","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"5731469","version":"1","preferredName":"Molecular Analysis Laboratory Procedure Epstein-Barr Nuclear Antigen 2 Gene Rearrangement Polymerase Chain Reaction Finding","preferredDefinition":"A laboratory procedure that involves the study of tissues, cells, and fluids using DNA/RNA analysis techniques for the identification of characteristics and abnormalities at the molecular level._Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Epstein-Barr nuclear antigen 2 (487 aa, ~55 kDa) is encoded by the Epstein-Barr virus EBNA2 gene. This protein is involved in the activation of host B-cells._Any DNA sequence rearrangement that results in the creation of a novel protein-coding capacity. Within certain genes, gene rearrangement is a normal part of development, facilitating the affinity maturation of B and T lymphocytes as well as class switching of immunoglobulins._A laboratory method used to make many copies of a specific DNA sequence._Clinical, laboratory or molecular evidence, or absence of evidence of disease.","longName":"2761442v1.0:5731535v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"2761442","version":"1","preferredName":"Molecular Analysis Laboratory Procedure","preferredDefinition":"Techniques for studying or analyzing the genetic composition and mechanisms of living organisms at the molecular level. May refer to the understanding and manipulation of genes (DNA).:A medical procedure that involves testing a sample of blood, urine, or other substance from the body. Tests can help determine a diagnosis, plan treatment, check to see if treatment is working, or monitor the disease over time.","longName":"C19770:C25294","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Molecular Analysis","conceptCode":"C19770","definition":"A laboratory procedure that involves the study of tissues, cells, and fluids using DNA/RNA analysis techniques for the identification of characteristics and abnormalities at the molecular level.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"50E37E4B-B5B3-5DA2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-06-30","endDate":null,"createdBy":"STURGILLJ","dateCreated":"2008-06-30","modifiedBy":"ONEDATA","dateModified":"2008-06-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5731535","version":"1","preferredName":"Epstein-Barr Nuclear Antigen 2 Gene Rearrangement Polymerase Chain Reaction Finding","preferredDefinition":"Epstein-Barr nuclear antigen 2 (487 aa, ~55 kDa) is encoded by the Epstein-Barr virus EBNA2 gene. This protein is involved in the activation of host B-cells.:Any DNA sequence rearrangement that results in the creation of a novel protein-coding capacity. Within certain genes, gene rearrangement is a normal part of development, facilitating the affinity maturation of B and T lymphocytes as well as class switching of immunoglobulins.:A method for amplifying a DNA base sequence using multiple rounds of heat denaturation of the DNA and annealing of oligonucleotide primers complementary to flanking regions in the presence of a heat-stable polymerase.  This results in duplication of the targeted DNA region. Newly synthesized DNA strands can subsequently serve as additional templates for the same primer sequences, so that successive rounds of primer annealing, strand elongation, and dissociation produce rapid and highly specific amplification of the desired sequence. PCR also can be used to detect the existence of the defined sequence in a DNA sample.:Clinical, laboratory or molecular evidence, or absence of evidence of disease.","longName":"C104664:C16611:C17003:C3367","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epstein-Barr Nuclear Antigen 2","conceptCode":"C104664","definition":"Epstein-Barr nuclear antigen 2 (487 aa, ~55 kDa) is encoded by the Epstein-Barr virus EBNA2 gene. This protein is involved in the activation of host B-cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Gene Rearrangement Process","conceptCode":"C16611","definition":"Any DNA sequence rearrangement that results in the creation of a novel protein-coding capacity. Within certain genes, gene rearrangement is a normal part of development, facilitating the affinity maturation of B and T lymphocytes as well as class switching of immunoglobulins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Polymerase Chain Reaction","conceptCode":"C17003","definition":"A method for amplifying a DNA base sequence using multiple rounds of heat denaturation of the DNA and annealing of oligonucleotide primers complementary to flanking regions in the presence of a heat-stable polymerase.  This results in duplication of the targeted DNA region. Newly synthesized DNA strands can subsequently serve as additional templates for the same primer sequences, so that successive rounds of primer annealing, strand elongation, and dissociation produce rapid and highly specific amplification of the desired sequence. PCR also can be used to detect the existence of the defined sequence in a DNA sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Finding","conceptCode":"C3367","definition":"Clinical, laboratory or molecular evidence, or absence of evidence of disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C0C74FA-AADF-1D8F-E053-F662850AE775","latestVersionIndicator":"Yes","beginDate":"2017-03-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-03-31","modifiedBy":"ONEDATA","dateModified":"2017-03-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C0C6BC9-7810-1D39-E053-F662850AB1C1","latestVersionIndicator":"Yes","beginDate":"2017-03-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-03-31","modifiedBy":"COOPERM","dateModified":"2017-03-31","changeDescription":"Created for 16C0003 Molecular Pathology CRF request by Y.Yakovlev. mc 3/31/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2181231","version":"1","preferredName":"Descriptive Text","preferredDefinition":"The text that provides a description of a topic.","longName":"DESCR_TXT","context":"DCP","contextVersion":"1","type":"Non-enumerated","dataType":"ALPHANUMERIC","minLength":"1","maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234203","version":"1","preferredName":"Text","preferredDefinition":"Text; the words of something written.","longName":"C25704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F89B-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"D3B72801-8C4C-3772-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-02-19","endDate":null,"createdBy":"CURTIST","dateCreated":"2004-02-19","modifiedBy":"GDEEN","dateModified":"2022-05-31","changeDescription":"3/22/22 jk added \"Qualified\" RS as part of MCL quarterly content review.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"EBV (EBNA-2) PCR Findings","type":"Preferred Question Text","description":"EBV (EBNA-2) PCR Findings","url":null,"context":"CCR"}],"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C0CC691-D5A6-2C53-E053-F662850AF12C","latestVersionIndicator":"Yes","beginDate":"2017-03-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-03-31","modifiedBy":"COOPERM","dateModified":"2017-03-31","changeDescription":"Created for 16C0003 Molecular Pathology CRF request by Y.Yakovlev. mc 3/31/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}